Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + etakafusp alfa
- Development stage
- Unknown
- Lead developer
- Asher Biotherapeutics, Inc.
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
tarlatamab + etakafusp alfa is an investigational combination therapy being developed by Amgen in collaboration with Asher Biotherapeutics for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen combines tarlatamab (IMDELLTRA), a bispecific T-cell engager (BiTE) targeting delta-like ligand 3 (DLL3), with etakafusp alfa (AB248), a CD8+ T cell-selective interleukin-2 (IL-2) immunotherapy. Tarlatamab works by redirecting T cells to engage and lyse DLL3-expressing tumor cells, a common marker in SCLC. Etakafusp alfa is designed to selectively activate CD8+ effector T cells without stimulating regulatory T cells or other cells associated with IL-2 toxicity, thereby potentially enhancing the durability and magnitude of the T-cell response initiated by tarlatamab. The combination is currently being evaluated in the Phase 1b DeLLphi-311 clinical trial.
- Brand names
- IMDELLTRA
- Other names
- tarlatamab-dlleetakafusp alfaA-Amgen-small cell lung cancer
02
Targets
CD8B (Cluster of differentiation 8 beta chain)IL-2R (Interleukin-2/interleukin-15 receptor complex)CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on tarlatamab + etakafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + etakafusp alfa.